Market Research Logo

Global Hypercalcemia Treatment Market 2017-2021

Global Hypercalcemia Treatment Market 2017-2021

About Hypercalcemia Treatment

Hypercalcemia is a condition in which the calcium level in the blood is above normal. Too much calcium in the blood can weaken the bones, create stones in the kidneys, and interfere with the functioning of the heart and the brain. Hypercalcemia refers to the condition where too much calcium enters the extracellular fluid or when there is insufficient calcium excretion from the kidneys. The cases of hypercalcemia are mainly caused by malignancy or hyperparathyroidism. Hypercalcemia is an outcome of overactive parathyroid glands. These four tiny glands are located near thyroid gland and each of them are about the size of a rice grain.

Technavio’s analysts forecast the global hypercalcemia treatment market to grow at a CAGR of 5.44% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global hypercalcemia treatment market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Hypercalcemia Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Amgen
  • Merck
  • Novartis
  • OPKO Health
Other prominent vendors
  • DiaSorin
  • Rockwell Medical
  • Kyowa Hakko Kirin
  • Fujirebio
Market driver
  • Expanding label indications.
  • For a full, detailed list, view our report
Market challenge
  • Severe threat of damage to nervous system.
  • For a full, detailed list, view our report
Market trend
  • Growing focus on emerging economies.
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Hypercalcemia Treatment Market 2017-2021

Technavio recognizes the following companies as the key players in the global hypercalcemia treatment market: AbbVie, Amgen, Merck, Novartis, and OPKO Health.

Other Prominent Vendors in the market are: DiaSorin, Rockwell Medical, Kyowa Hakko Kirin, and Fujirebio.

Commenting on the report, an analyst from Technavio’s team said: “One trend in market is combination therapy. Although the preference for hypercalcemia drugs in developed countries is increasing, the use of hypercalcemia drugs in combination with other therapies will help maintain the adoption rates. For instance, researchers have evaluated the use of combination drugs, which include pamidronate and calcitonin. This should increase the demand for hypercalcemia drugs in developed countries.”

According to the report, one driver in market is expanding label indications. As the market is dominated by generic products, label extensions will provide more opportunities for revenue generation. This is expected to propel the market growth substantially. Vendors are also increasingly focusing on developing drugs for segments such as parathyroidism and CKD. For instance, in 2016, OPKO Health received approval from the US FDA for Rayaldee (extended-release capsules) for the treatment of SHPT in adults with CKD and serum total 25-hydroxyvitamin D. Also, in November 2016, Amgen received approval from the EC for Parsabiv (etelcalcetide) to treat SHPT in adults with CKD on hemodialysis. In September 2015, Rockwell Medical Launched Calcitriol in the US for the treatment of iron replacement, SHPT, and hemodialysis. The increase in label indications will expand the scope of hypercalcemia, thereby driving the market growth.

Further, the report states that one challenges in market is patent expiries of major drugs. Patent expiries result in the loss of an exclusive market for a drug, leading to a rapid decline in its sales. The introduction of low-cost drugs is likely to increase the competition in the market. The market has experienced the limited availability of branded products due to the patent expiry of major drugs such as Amgen’s Sensipar, which lost its patent in 2016. Similarly, AbbVie’s ZEMPLAR (paricalcitol) lost its patent in 2015, and Sanofi-Aventis US’s Hectorol (doxercalciferol), which was an intravenous for the treatment of SHPT, had lost its patent in 2014. Thus, the patent expiries of major drugs result in the decline of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit- https://www.technavio.com/report/global-health-and-wellness-global-hypercalcemia-treatment-market-2017-2021

Companies Mentioned

AbbVie, Amgen, Merck, Novartis, OPKO Health, DiaSorin, Rockwell Medical, Kyowa Hakko Kirin, and Fujirebio.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Key market highlights
  • An overview of Hypercalcemia
    • Table Body parts affected by high calcium
  • Pipeline Analysis
    • Table Pipeline landscape
  • Market landscape
    • Market overview
      • Table Global hypercalcemia treatment market snapshot
      • Table Global hypercalcemia treatment market 2016-2021 ($ millions)
      • Table Opportunity analysis in global hypercalcemia treatment market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by product type
    • Table Market segmentation by product type 2016
    • Bisphosphonates
      • Table Bisphosphonates segment 2016-2021 ($ millions)
    • Glucocorticoids
      • Table Glucocorticoids segment 2016-2021 ($ millions)
    • Calcimimetic agents
      • Table Calcimimetic agents segment 2016-2021 ($ millions)
    • Others
  • Market segmentation by geography
    • Table Global hypercalcemia treatment market by geography 2016 and 2021
    • Table Global hypercalcemia treatment market revenue by geography 2016-2021 ($ millions)
    • Hypercalcemia treatment market in Americas
      • Table Market scenario in Americas
      • Table Hypercalcemia treatment market in Americas ($ millions)
    • Hypercalcemia treatment market in EMEA
      • Table Market scenario in EMEA
      • Table Hypercalcemia treatment market in EMEA ($ millions)
    • Hypercalcemia treatment market in APAC
      • Table Market scenario in APAC
      • Table Hypercalcemia treatment market in APAC ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Key approvals
      • Table Key factors driving the market growth
    • Impact of drivers on key customer segments
      • Table Impact of drivers
    • Market challenges
      • Table Impact of serum calcium concentration
    • Impact of challenges on key customer segments
      • Table Impact of challenges
  • Market trends
    • Combination therapy
    • Increase in outsourcing
    • Growing focus on emerging economies
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global hypercalcemia treatment market 2016
      • Table Competitive analysis of global hypercalcemia market
  • Key vendor analysis
    • AbbVie
      • Table AbbVie: Key highlights
      • Table AbbVie: Strength assessment
      • Table AbbVie: Strategy assessment
      • Table AbbVie: Opportunity assessment
    • Amgen
      • Table Amgen: Key highlights
      • Table Amgen: Strength assessment
      • Table Amgen: Strategy assessment
      • Table Amgen: Opportunity assessment
    • Merck
      • Table Merck: Key highlights
      • Table Merck: Strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • Novartis
      • Table Novartis: Strength assessment
      • Table Novartis: Strategy assessment
      • Table Novartis: Opportunity assessment
    • OPKO Health
      • Table OPKO Health: Key highlights
      • Table OPKO Health: Strength assessment
      • Table OPKO Health: Strategy assessment
      • Table OPKO Health: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report